MGX
Metagenomi, Inc. Common Stock NASDAQ$1.41
Mkt Cap $53.0M
52w Low $1.25
5.9% of range
52w High $3.95
50d MA $1.46
200d MA $1.86
P/E (TTM)
-0.6x
EV/EBITDA
-0.7x
P/B
0.3x
Debt/Equity
0.3x
ROE
-55.4%
P/FCF
-0.7x
RSI (14)
—
ATR (14)
—
Beta
0.57
50d MA
$1.46
200d MA
$1.86
Avg Volume
230.5K
About
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated trans…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.58 | -0.60 | -3.4% | 1.61 | -3.7% | -8.1% | -0.6% | +9.3% | +1.9% | -2.5% | — |
| Nov 11, 2025 | AMC | -0.60 | -0.55 | +8.3% | 2.20 | -9.1% | -15.5% | -22.7% | -20.9% | -22.7% | -22.7% | — |
| Aug 12, 2025 | AMC | -0.68 | -0.54 | +20.6% | 1.88 | +2.1% | +3.2% | +1.1% | -1.1% | +2.1% | -2.7% | — |
| May 13, 2025 | AMC | -0.62 | -0.68 | -9.7% | 1.60 | +0.6% | -6.2% | -2.5% | +3.8% | +6.9% | +6.2% | — |
| Mar 17, 2025 | AMC | -0.62 | -0.63 | -1.6% | 1.88 | -1.6% | -8.0% | -9.0% | -10.6% | -12.8% | -12.2% | — |
| Nov 13, 2024 | AMC | -0.70 | -0.45 | +35.7% | 2.11 | +9.0% | -10.9% | -13.7% | -17.1% | -19.9% | -21.8% | — |
| Aug 14, 2024 | AMC | -0.59 | -0.29 | +50.8% | 3.10 | -2.6% | -5.5% | -9.0% | +1.6% | +6.5% | +7.1% | — |
| May 14, 2024 | AMC | -0.95 | -1.19 | -25.3% | 6.54 | -0.6% | +4.0% | +7.0% | +7.0% | +2.3% | +8.6% | — |
| Feb 10, 2024 | AMC | -2.04 | -0.51 | +74.8% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.53 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.92 | $1.94 | +1.0% | -4.7% | -3.6% | -3.6% | +0.5% | -2.1% |
| Aug 15 | Chardan Capital | Maintains | Buy → Buy | — | $1.90 | $1.84 | -3.2% | -2.1% | +1.1% | -3.7% | -2.6% | -2.6% |
| Aug 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $1.94 | $1.95 | +0.5% | -2.1% | -4.1% | -1.0% | -5.7% | -4.6% |
| May 15 | Chardan Capital | Maintains | Buy → Buy | — | $1.50 | $1.50 | +0.0% | +4.0% | +10.7% | +14.0% | +13.3% | +10.0% |
| May 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $1.60 | $1.61 | +0.6% | -6.2% | -2.5% | +3.8% | +6.9% | +6.2% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.33 | $1.33 | +0.0% | -5.3% | +6.0% | +7.5% | +5.3% | +12.8% |
| Mar 18 | Wells Fargo | Maintains | Overweight → Overweight | — | $1.88 | $1.85 | -1.6% | -8.0% | -9.0% | -10.6% | -12.8% | -12.2% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.17 | $4.22 | +1.2% | +0.5% | -5.3% | -7.4% | -22.3% | -25.4% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.65 | $1.67 | +1.2% | +10.3% | +14.5% | +21.8% | +21.8% | +22.4% |
| Nov 20 | Chardan Capital | Maintains | Buy → Buy | — | $1.69 | $1.70 | +0.6% | -2.4% | +7.7% | +11.8% | +18.9% | +18.9% |
Recent Filings
Data updated apr 26, 2026 12:11pm
· Source: massive.com